WO2022135200A1 - 一种抗体缀合物、增强抗体分子免疫效应功能的方法 - Google Patents

一种抗体缀合物、增强抗体分子免疫效应功能的方法 Download PDF

Info

Publication number
WO2022135200A1
WO2022135200A1 PCT/CN2021/137352 CN2021137352W WO2022135200A1 WO 2022135200 A1 WO2022135200 A1 WO 2022135200A1 CN 2021137352 W CN2021137352 W CN 2021137352W WO 2022135200 A1 WO2022135200 A1 WO 2022135200A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
molecule
rha
hapten
peg
Prior art date
Application number
PCT/CN2021/137352
Other languages
English (en)
French (fr)
Inventor
吴志猛
洪皓飞
周坤
周志昉
Original Assignee
江南大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江南大学 filed Critical 江南大学
Priority to EP21909197.2A priority Critical patent/EP4265273A1/en
Publication of WO2022135200A1 publication Critical patent/WO2022135200A1/zh
Priority to US18/337,631 priority patent/US20230364257A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention belongs to the technical field of pharmaceutical engineering, in particular to an antibody conjugate and a method for enhancing the immune effector function of antibody molecules.
  • Monoclonal antibodies are currently one of the most effective anti-tumor biotherapeutics. They exert therapeutic effects by targeting tumor-specific antigens or related antigens.
  • the main mechanisms include: inducing or blocking cell signaling, activating immune effector functions, and As a carrier to specifically deliver drugs to target cells, etc.
  • immune effector function refers to the ability of antibodies to activate various effector functions including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which is the most anti-tumor function.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • CDC complement-dependent cytotoxicity
  • the most basic function of antibody drugs Therefore, further enhancing their ADCC and CDC activities by means of antibody engineering is a hot spot in the research and development of antibody biomedicine.
  • the use of antibody genetic engineering technology to transform antibodies is the main method to enhance the ADCC and CDC activities of antibodies, and some new-generation monoclonal antibodies with enhanced ADCC and CDC activities have been obtained through this method.
  • the disadvantage is that the antibody genetic engineering technology is relatively complex, requiring a lot of screening to obtain antibodies with better immune activity, and the workload is large; in addition, the modified antibodies have certain immunogenicity, which will cause immune side effects. .
  • the present invention provides an antibody conjugate and a method for enhancing the immune effector function of antibody molecules, specifically a strategy based on the recruitment of hapten-specific natural antibodies. And through the optimization of the linking arm, a hapten derivative molecule after optimized screening is provided, so that the antibody modified by the molecule has the immune effect function obviously better than other reported antibodies.
  • An object of the present invention is to provide an antibody conjugate obtained by modifying an antibody molecule with a hapten derivative molecule, wherein the hapten derivative molecule is composed of a hapten, a linker and a coupling domain.
  • the haptens of the present invention are small molecules that can recruit natural antibodies in the human body, including anti-rhamnose (Rha) antibodies, anti-2,4-dinitrobenzene (DNP) antibodies that are highly abundant in the human body.
  • Antibodies and anti- ⁇ Gal antibodies, ie, the haptens are preferably Rha, DNP or ⁇ Gal and the like.
  • the linking arm of the present invention is used to connect the hapten and the coupling domain, including but not limited to polyethylene glycol chain, carbon chain and peptide chain.
  • the linking arm is preferably oligoethylene glycol (molecular weight less than 1000), short carbon chain (molecular weight less than 100) and peptide chain, and further, preferably low polyethylene glycol PEG 3 .
  • the coupling domain of the present invention is used to modify the hapten derivative on the antibody.
  • the coupling position is preferably on the antibody.
  • the coupling domain is preferably SMCC containing maleimide molecules, and can also be replaced with other molecules containing maleimides (maleimides, ), and vinyl sulfones-containing molecules (vinyl sulfones, ), molecules containing acrylates and/or acrylates (acrylates&acrylamides, ), 3,4-dibromosuccinimide-containing molecules and methacrylate-containing molecules (methacrylates, ), R is any organic group.
  • the antibodies of the present invention are monoclonal antibodies, preferably some monoclonal antibodies that have been marketed or commercially available.
  • Illustrative examples include, but are not limited to, anti-CD20 antibodies, anti-CD19 antibodies, anti-CD30 antibodies, anti-EGFR antibodies, anti-EGFRvIII antibodies, anti-HER2 antibodies, anti-HER3 antibodies, anti-PSMA antibodies, anti-VEGFR antibodies, anti-PD-L1 antibodies, Anti-cMET antibody, anti-TGF-beta antibody, anti-MUC1 antibody and anti-Trop-2 antibody.
  • amino acid sequence of the antibody molecule is: heavy chain amino acids as shown in SEQ ID NO.1 and light chain amino acids as shown in SEQ ID NO.2.
  • the hapten derivative molecule includes:
  • n is a positive integer
  • Another object of the present invention is to also provide a method for improving the immune effector function of antibody molecules, that is, by modifying hapten derivative molecules on antibody molecules, and utilizing the natural antibody recruitment ability of hapten molecules to enhance ADCC and CDC, etc. purpose of immune activity. Finally, through the optimization of the hapten derivative linker, the antibody conjugate with the most prominent immune effector function was further screened.
  • hapten derivatives, antibody molecules, modification positions and methods involved in improving the immune effector function of antibody molecules according to the present invention are as described above.
  • the method for preparing an antibody conjugate by modifying a hapten derivative molecule onto an antibody molecule comprises the following steps:
  • the selected antibody molecule is the anti-CD20 monoclonal antibody Rituximab (Rituximab, KEGG Accession Number: DB00073, the heavy chain is shown in SEQ ID NO.1, and the light chain is shown in SEQ ID NO.2 shown), CD20 is highly expressed on the surface of more than 95% of B-cell lymphoma cells, making it an important target for targeted monoclonal therapy.
  • the optimized hapten derivative molecule is SMCC-PEG 3 -Rha SMCC is the coupling domain, PEG 3 is an oligoethylene glycol chain, and Rha is a hapten.
  • the coupling position is the 8 sulfhydryl groups formed by the reduction of the four disulfide bonds on the Rituxan antibody.
  • the antibody conjugate of the present invention is not inhibited in the level of antigen affinity; on the other hand, has significantly enhanced ADCC and CDC activities. Therefore, the dosage can be reduced during the treatment, and finally the occurrence of some toxic and side effects can be reduced or avoided to a certain extent.
  • Figure 1 Protein profile. Light chain protein profiling results of Rituxan antibody and Rituxan antibody conjugates ⁇ CD20-PEG 1 -Rha, ⁇ CD20-PEG 3 -Rha and ⁇ CD20-PEG 6 -Rha.
  • Figure 2 Flow cytometric characterization.
  • A Evaluation of affinity levels of Rituxan antibody and Rituxan antibody conjugates ⁇ CD20-PEG 1 -Rha, ⁇ CD20-PEG 3 -Rha and ⁇ CD20-PEG 6 -Rha;
  • B Rituxan antibody and Rituxan antibody conjugate ⁇ CD20- Evaluation of anti-Rha antibody recruitment ability of PEGi-Rha, ⁇ CD20 - PEG3 - Rha and ⁇ CD20-PEG6 - Rha.
  • FIG. 3 ADCC characterization.
  • A ADCC levels of different concentrations of Rituxan antibody and Rituxan antibody conjugates ⁇ CD20-PEG 1 -Rha, ⁇ CD20-PEG 3 -Rha and ⁇ CD20-PEG 6 -Rha in the absence of anti-Rha antibody;
  • B in the presence of ADCC levels of rituximab antibody and rituximab antibody conjugates ⁇ CD20-PEG 1 -Rha, ⁇ CD20-PEG 3 -Rha and ⁇ CD20-PEG 6 -Rha at different concentrations for anti-Rha antibody.
  • Figure 4 CDC characterization.
  • A CDC levels of different concentrations of Rituxan antibody and Rituxan antibody conjugates ⁇ CD20-PEG 1 -Rha, ⁇ CD20-PEG 3 -Rha and ⁇ CD20-PEG 6 -Rha in the absence of anti-Rha antibody;
  • B in the presence of CDC levels of rituximab antibody and rituximab antibody conjugates ⁇ CD20-PEG 1 -Rha, ⁇ CD20-PEG 3 -Rha and ⁇ CD20-PEG 6 -Rha at different concentrations for anti-Rha antibody.
  • the invention discloses an antibody conjugate and a method for improving the immune effector function of antibody molecules.
  • the antibody conjugate is obtained by modifying an antibody molecule with a hapten derivative molecule, and the hapten refers to a small molecule that can recruit specific natural antibodies in the human body.
  • the hapten is modified on the antibody molecule by a mild and simple method, and the obtained antibody conjugate not only retains the excellent affinity level of the original antibody, but also can recruit the corresponding specific natural antibody to the tumor cells, thereby To achieve the purpose of improving immune effector functions such as antibody ADCC and CDC.
  • the present invention also obtains an antibody conjugate that can cause the highest level of immune effector function by optimizing the length of the linker arm of the hapten derivative molecule.
  • the hapten derivative molecule SMCC-PEG-Rha is synthesized, and then the SMCC-PEG-Rha is modified on the antibody molecule, thereby preparing the corresponding antibody conjugate.
  • the coupling domain is selected as SMCC
  • the connecting arm is selected as PEG
  • the hapten is selected as Rha
  • the synthesized hapten derivative molecule is SMCC-PEG-Rha, and different experiments are carried out focusing on the length of the connecting arm. Validation for optimal tether length.
  • Embodiment 1 the preparation containing different link arm hapten derivatives SMCC-PEG-Rha
  • the final protein spectrum is shown in Figure 1.
  • the results show that the molecular weight of the light chain of the Rituxan antibody is 23131 Da, the molecular weight of the light chain of the Rituxan antibody ⁇ CD20-PEG 1 -Rha is 23557 Da, and the molecular weight of the light chain of the antibody conjugate ⁇ CD20-PEG 3 -Rha is The molecular weight of the light chain of the antibody conjugate ⁇ CD20-PEG 6 -Rha is 23645 Da and 23777 Da, all in accordance with the theory.
  • FIG. 2B The results of the anti-Rha antibody recruitment ability are shown in Figure 2B.
  • the Raji cells treated with the antibody conjugate only had a significant increase in fluorescence, indicating that the Rituxan antibody successfully recruited the anti-Rha antibody after being modified by Rha. to the surface of CD20-positive tumor cells.
  • FIG. 2B also shows that the antibody conjugate ⁇ CD20-PEG 3 -Rha has the highest level of anti-Rha antibody recruitment ability.
  • Embodiments of the cytotoxicity assay are shown below, with ADCC and CDC activity assessed both in the presence and absence of anti-Rha antibodies.
  • ADCC experiment 1) Take Raji cells in good growth condition, resuspend them to 4 ⁇ 10 5 cells/mL, and transfer 50 ⁇ L of cell suspension to a 96-well culture plate; 2) Immediately add 50 ⁇ L of Rituxan or Rituxan antibody conjugates with different concentrations Compound PBS solution, 50 ⁇ L of 4% anti-Rha rabbit serum (or the same volume of PBS) and 50 ⁇ L of freshly isolated PBMC, treated at 37°C for 4 h; 3) LDH kit to detect cytotoxicity.
  • CDC experiment 1) Take well-growing Raji cells, resuspend to 4 ⁇ 10 5 cells/mL, and transfer 50 ⁇ L of cell suspension to a 96-well culture plate; 2) Immediately add 50 ⁇ L of rituximab containing different concentrations or its conjugates PBS solution, 50 ⁇ L of 4% anti-Rha rabbit serum (or the same volume of PBS) and 50 ⁇ L of 8% rabbit complement serum, treated at 37°C for 4 h; 3) LDH kit to detect cytotoxicity.
  • the CDC level of the conjugate ⁇ CD20-PEG 3 -Rha was the highest, reaching 69.3% at the treatment concentration of 0.1 nM, which was significantly higher than the CDC level (53.2%) after treatment with the original antibody at 2.5 nM.
  • the amount of ⁇ CD20-PEG 3 -Rha used only needs to be 1/25 or even less than that of the original antibody.
  • ADCC and CDC levels of ⁇ CD20-PEG 3 -Rha are the highest, that is, the killing levels of ADCC and CDC are significantly enhanced.
  • the ADCC and CDC levels of the relatively short-chain ⁇ CD20-PEG 1 -Rha and the relatively long-chain ⁇ CD20-PEG 6 -Rha were correspondingly lower.
  • the short-chain ⁇ CD20-PEG 1 -Rha The recruitment level of anti-Rha antibodies is limited, so that the killing levels of ADCC and CDC cannot be improved; on the other hand, the affinity level of long-chain ⁇ CD20-PEG 6 -Rha with anti-Rha antibodies may be due to affinity weakened, resulting in the inhibition of the ADCC and CDC killing levels, and did not achieve the effect of the positive correlation commission killing level as expected by the existing theory.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

一种抗体缀合物、增强抗体分子免疫效应功能的方法。所述抗体缀合物由抗体分子经半抗原衍生物分子修饰所得，所述半抗原衍生物由半抗原、连接臂和耦合域组成。通过温和简便的方法将半抗原衍生物修饰在抗体分子上，所获得的抗体缀合物不仅保留了原有抗体的优良亲和水平，还可以招募相应的特异性天然抗体至肿瘤细胞上，从而达到显著提高抗体ADCC和CDC等免疫效应功能的目的。此外，还通过对连接臂长度的优化，优化得到了SMCC-PEG 3-Rha这一半抗原衍生物。相比于其它已报道的抗体分子，SMCC-PEG 3-Rha修饰的抗体，具备更加突出的免疫效应功能。

Description

一种抗体缀合物、增强抗体分子免疫效应功能的方法 技术领域
本发明属于制药工程技术领域，具体涉及一种抗体缀合物、增强抗体分子免疫效应功能的方法。
背景技术
恶性肿瘤目前依然是威胁人类健康的主要疾病，其发病和死亡人数均呈逐年上升趋势。单克隆抗体是目前最有效的抗肿瘤生物治疗剂之一，它们通过靶向肿瘤特异性抗原或者相关性抗原来发挥治疗作用，主要机制包括：诱导或阻断细胞信号，激活免疫效应功能，以及作为载体将药物特异性输送到靶细胞等。其中，免疫效应功能是指抗体所具备的，激活包括抗体依赖细胞介导的细胞毒作用(ADCC)和补体依赖的细胞毒作用(CDC)在内的多种效应作用的能力，是多数抗肿瘤抗体药物最为基本的功能。因此，通过抗体工程手段，进一步增强它们的ADCC和CDC活性是目前抗体生物医药研发的热点。
目前，使用抗体基因工程技术改造抗体是增强抗体ADCC和CDC活性的主要手段，通过该手段已经获得一些ADCC和CDC活性增强的新一代单克隆抗体。然而，不足之处是，抗体基因工程技术比较复杂，需要经过大量的筛选才能获得免疫活性较好的抗体，工作量较大；另外，改造后的抗体具有一定的免疫原性，会引起免疫副作用。
人体内存在着一些半抗原特异性天然抗体，丰度较高的有抗Rha抗体、抗DNP抗体和抗αGal抗体。通过在商业化单克隆抗体上修饰这些半抗原分子，将有望达到改善原有抗体免疫效应功能的目的。如有学者报道，通过将αGal衍生物修饰到抗CD20抗体上，可以获得CDC水平增强型的抗CD20抗体。但一方面其修饰方法复杂，会对抗体的亲和性，以及产物的稳定性和产率产生影响；另一方面，其未对所得抗体的另一个主要免疫效应功能，即ADCC水平进行评估；也未对重要的影响因素，连接臂的长度进行优化。最终导致其产物的免疫效应功能水平提升有限。
因此，亟需一种新的增强抗体免疫效应功能的方法，以缓解或解决上述问题。
发明内容
发明目的：为了克服现有技术中存在的不足，本发明提供一种抗体缀合物、增强抗体分子免疫效应功能的方法，具体是一种基于半抗原特异性天然抗体募集的策略。并通 过连接臂优化，提供一种优化筛选后的半抗原衍生物分子，使得经该分子修饰的抗体具备明显优于其它已报道抗体的免疫效应功能。
技术方案：为实现上述目的，本发明采用的技术方案为：
本发明的一个目的是，提供一种抗体缀合物，由抗体分子被半抗原衍生物分子修饰得到，所述的半抗原衍生物分子由半抗原、连接臂和耦合域构成。
进一步的，本发明所述半抗原为可募集人体内天然抗体的小分子，包括在人体内丰度较高的抗鼠李糖(Rha)抗体，抗2,4-二硝基苯(DNP)抗体和抗αGal抗体，即所述的半抗原优选为Rha、DNP或αGal等。
进一步的，本发明所述的连接臂用于连接半抗原和耦合域，包括但不限于聚乙二醇链、碳链和肽链。为了便于合成均一的产物以及减少不期望的毒副作用，所述连接臂优选为低聚乙二醇(分子量小于1000)、短碳链(分子量小于100)和肽链，更进一步的，优选为低聚乙二醇PEG 3。
进一步的，本发明所述的耦合域用于将半抗原衍生物修饰在抗体上，为了便于合成均一的产物以及减少半抗原衍生物对抗体原有亲和性的影响，耦合位置优选为抗体上四个二硫键还原后所形成的8个巯基；耦合域优选为含马来酰亚胺分子的SMCC，也可换做其它的含马来酰亚胺的分子(maleimides，
Figure PCTCN2021137352-appb-000001
)，以及含乙烯基砜的分子(vinyl sulfones，
Figure PCTCN2021137352-appb-000002
)、含丙烯酸脂和/或丙烯酸胺的分子(acrylates&acrylamides，
Figure PCTCN2021137352-appb-000003
)、含3,4-二溴丁二酰亚胺的分子和含甲基丙烯酸酯的分子(methacrylates，
Figure PCTCN2021137352-appb-000004
)，R为任意有机基团。
进一步的，本发明所述的抗体为单克隆抗体，优选为一些已经上市或商业可获得的单克隆抗体。可列举的实例包括但不限于抗CD20抗体、抗CD19抗体、抗CD30抗体、抗EGFR抗体、抗EGFRvIII抗体、抗HER2抗体、抗HER3抗体、抗PSMA抗体、抗VEGFR抗体、抗PD-L1抗体、抗cMET抗体、抗TGF-β抗体、抗MUC1抗体和抗Trop-2抗体。
进一步的，所述抗体分子的氨基酸序列为：如SEQ ID NO.1所示的重链氨基酸和如SEQ ID NO.2所示的轻链氨基酸。
进一步的，所述半抗原衍生物分子包括：
Figure PCTCN2021137352-appb-000005
更进一步的，所述半抗原衍生物的合成路径为：
Figure PCTCN2021137352-appb-000006
其中，n为正整数。
本发明的另一个目的，是还提供一种提高抗体分子免疫效应功能的方法，即通过将半抗原衍生物分子修饰到抗体分子上，利用半抗原分子的天然抗体招募能力达到增强ADCC和CDC等免疫活性的目的。并最终通过对半抗原衍生物连接臂的优化，进一步筛选得到免疫效应功能最为突出的抗体缀合物。
本发明所述的提高抗体分子免疫效应功能所涉及的半抗原衍生物、抗体分子、修饰位置和方法等如前所述。
进一步的，所述将半抗原衍生物分子修饰到抗体分子上制备抗体缀合物的方法包括以下步骤：
1)将抗体脱盐置换到硼酸钠反应中；
2)加入硫醇类还原剂TCEP避光震荡反应；
3)反应完成后加入10倍当量的半抗原衍生物分子，反应后经半胱氨酸淬灭反应；
4)超滤除去多余的小分子，得到相应的抗体缀合物。
在本发明的一种具体实施方式中，所选抗体分子为抗CD20单克隆抗体美罗华 (Rituximab，KEGG Accession Number:DB00073，重链如SEQ ID NO.1所示，轻链如SEQ ID NO.2所示)，CD20在95％以上的B细胞性淋巴瘤细胞表面高表达，这个特性使之成为靶向单克隆治疗的重要靶点。优化后的半抗原衍生物分子为SMCC-PEG 3-Rha
Figure PCTCN2021137352-appb-000007
其中SMCC为耦合域，PEG 3为低聚乙二醇链，Rha为半抗原。耦合位置为美罗华抗体上四个二硫键还原后所形成的8个巯基。
有益效果：本发明相对于现有技术的优势：
(1)本发明所述的抗体缀合物，与现有报道抗体相比，一方面抗原亲和水平未受到抑制；另一方面，具备显著增强的ADCC和CDC活性。从而在治疗时可以降低使用剂量，最终在一定程度上减少或避免一些毒副作用的产生。
(2)本发明所提供的优化后的半抗原衍生物，其所对应的抗体缀合物具备最突出的免疫效应功能，仅采用野生型始抗体4％的用量，即可展现出显著高于野生型抗体的CDC杀伤效果。
(3)本发明所述的增强抗体免疫效应功能的策略，一方面操作简单，修饰条件温和；另一方面由于利用的是机体自身的天然抗体，从而避免了潜在的毒性和免疫原性。
附图说明
图1：蛋白质谱图。美罗华抗体及美罗华抗体缀合物αCD20-PEG 1-Rha、αCD20-PEG 3-Rha和αCD20-PEG 6-Rha的轻链蛋白质谱结果。
图2：流式细胞表征。(A)美罗华抗体及美罗华抗体缀合物αCD20-PEG 1-Rha、αCD20-PEG 3-Rha和αCD20-PEG 6-Rha的亲和水平评估；(B)美罗华抗体及美罗华抗体缀合物αCD20-PEG 1-Rha、αCD20-PEG 3-Rha和αCD20-PEG 6-Rha的抗Rha抗体募集能力评估。
图3：ADCC表征。(A)在不存在抗Rha抗体时，不同浓度美罗华抗体及美罗华抗体缀合物αCD20-PEG 1-Rha、αCD20-PEG 3-Rha和αCD20-PEG 6-Rha的ADCC水平；(B)在存在抗Rha抗体时，不同浓度美罗华抗体及美罗华抗体缀合物αCD20-PEG 1-Rha、αCD20-PEG 3-Rha和αCD20-PEG 6-Rha的ADCC水平。
图4：CDC表征。(A)在不存在抗Rha抗体时，不同浓度美罗华抗体及美罗华抗体缀合物αCD20-PEG 1-Rha、αCD20-PEG 3-Rha和αCD20-PEG 6-Rha的CDC水平；(B)在存在抗Rha抗体时，不同浓度美罗华抗体及美罗华抗体缀合物αCD20-PEG 1-Rha、 αCD20-PEG 3-Rha和αCD20-PEG 6-Rha的CDC水平。
具体实施方式
本发明公开了一种抗体缀合物，提高抗体分子免疫效应功能的方法。所述抗体缀合物为抗体分子被半抗原衍生物分子修饰所得，所述半抗原是指可招募人体内特异性天然抗体的小分子。本发明通过温和简便的方法将半抗原修饰在抗体分子上，所获得的抗体缀合物不仅保留了原有抗体的优良亲和水平，还可以招募相应的特异性天然抗体至肿瘤细胞上，从而达到提高抗体ADCC和CDC等免疫效应功能的目的。本发明还通过对半抗原衍生物分子的连接臂长度进行优化，获得了可引起最高水平免疫效应功能的抗体缀合物。
下面结合实施例对本发明做进一步说明，应当理解，此处所描述的具体实施例仅用以解释本发明，并不用于限定本发明，凡在本发明的构思前提下对本发明制备方法的简单改进都属于本发明的保护范围之内。下面实施例未注明具体条件的实验方法，通常按照本领域的公知手段。下述实施例中所用的试验材料和细胞系，如无特殊说明，均为自常规试剂公司购买得到。
实施例
根据本发明的抗体缀合物的合成方法，首先是合成半抗原衍生物分子SMCC-PEG-Rha，然后是将SMCC-PEG-Rha修饰到抗体分子上，从而制备得到相应的抗体缀合物。本发明实施例中，耦合域选用为SMCC，连接臂选用为PEG，半抗原选用为Rha，合成的半抗原衍生物分子为SMCC-PEG-Rha，并且重点针对连接臂的长短进行了不同的实验验证，以获得最优的连接臂长度。
根据下述实施例，可以更好的理解本发明。然而，本领域的技术人员容易理解，实施例所描述的具体的耦合域、连接臂、半抗原及其结果仅用于说明本发明，而不应当也不会限制权利要求书中所详细描述的本发明的技术方案。
实施例1:含不同连接臂半抗原衍生物SMCC-PEG-Rha的制备
(1)半抗原衍生物SMCC-PEG 1-Rha的合成路径和条件如下图所示：
Figure PCTCN2021137352-appb-000008
经检测，终产物的核磁和质谱结果均与预期一致，表明所合成的SMCC-PEG 1-Rha正确。 1H NMR(400MHz,Methanol-d4)δ6.80(s,2H),4.66(d,J＝1.7Hz,1H),3.79(dd,J＝3.5,1.7Hz,1H),3.69(dt,J＝10.0,5.7Hz,1H),3.63(dd,J＝9.5,3.5Hz,1H),3.58–3.51(m,1H),3.45(ddd,J＝10.3,6.1,4.7Hz,1H),3.40–3.31(m,6H),2.14(tt,J＝12.2,3.5Hz,1H),1.82(dd,J＝13.5,3.4Hz,2H),1.76–1.69(m,2H),1.42(qd,J＝13.1,3.3Hz,2H),1.24(d,J＝6.2Hz,3H),1.00(qd,J＝13.1,3.5Hz,2H). 13C NMR(101MHz,Methanol-d4)δ177.68,171.37,133.87,100.27,72.53,70.94,70.75,68.48,65.55,44.70,43.12,38.74,36.49,29.58,28.66,16.60.HRMS(ESI,positive)calcd for C 20H 30N 2O 8Na[M+Na] +:449.1900Found:449.1899.
(2)半抗原衍生物SMCC-PEG 3-Rha的合成路径和条件如下图所示：
Figure PCTCN2021137352-appb-000009
经检测，终产物的核磁和质谱结果均与预期一致，表明所合成的SMCC-PEG 3-Rha正确。 1H NMR(400MHz,Methanol-d4)δ6.71(s,2H),4.62(d,J＝1.7Hz,1H),3.73–3.65(m,2H),3.57–3.49(m,8H),3.43(t,J＝5.5Hz,2H),3.30–3.19(m,6H),2.05(tt,J＝12.1, 3.4Hz,1H),1.72(dd,J＝13.5,3.5Hz,2H),1.66–1.60(m,2H),1.38–1.20(m,3H),1.16(d,J＝6.2Hz,3H),0.91(qd,J＝12.9,3.5Hz,2H). 13C NMR(101MHz,Methanol-d4)δ133.88,100.41,72.59,70.99,70.82,70.26,70.05,69.27,68.41,66.30,48.27,48.05,47.84,47.63,47.41,47.20,46.99,44.67,43.14,38.86,29.57,28.63.HRMS(ESI,positive)calcd for C 24H 38N 2O 10Na[M+Na] +:537.2424Found:537.2415.
(3)半抗原衍生物SMCC-PEG 6-Rha的合成路径和条件如下图所示：
Figure PCTCN2021137352-appb-000010
经检测，终产物的核磁和质谱结果均与预期一致，表明所合成的SMCC-PEG 6-Rha正确。 1H NMR(400MHz,Methanol-d4)δ6.81(s,2H),4.71(d,J＝1.7Hz,1H),3.82–3.75(m,2H),3.68–3.57(m,22H),3.52(t,J＝5.5Hz,2H),3.40–3.31(m,5H),2.15(tt,J＝12.2,3.6Hz,1H),1.82(dd,J＝13.7,3.5Hz,2H),1.76–1.69(m,2H),1.42(qd,J＝13.1,3.3Hz,2H),1.25(d,J＝6.2Hz,3H),1.01(qd,J＝12.9,3.6Hz,2H). 13C NMR(101MHz,Methanol-d4)δ171.39,133.89,100.43,72.61,70.98,70.81,70.28,70.22,70.20,70.18,70.16,70.13,70.02,69.88,69.19,68.41,66.40,44.67,43.14,38.86,36.51,29.60,28.63,16.67.HRMS(ESI,positive)calcd for C 30H 51N 2O 10[M+H] +:647.3391Found:647.3389
实施例2：美罗华抗体缀合物的制备
制备美罗华抗体缀合物的实施方案为：
1)将美罗华抗体脱盐置换到25mM硼酸钠反应中；
2)加入硫醇类还原剂TCEP避光震荡，期间Ellman试剂巯基数监测反应完成情况；
3)反应完成后加入10倍当量由实施例1制备得到的SMCC-PEG 1-Rha或SMCC-PEG 3-Rha或SMCC-PEG 6-Rha反应一段时间，半胱氨酸淬灭反应；
4)超滤法除去多余的小分子，即可得到相应的三种美罗华抗体缀合物αCD20-PEG 1-Rha、αCD20-PEG 3-Rha、αCD20-PEG 6-Rha。
最后蛋白质谱如图1所示，结果表明美罗华抗体轻链的分子量为23131Da，美罗华抗体αCD20-PEG 1-Rha的轻链分子量为23557Da，抗体缀合物αCD20-PEG 3-Rha的轻链分子量为23645Da，抗体缀合物αCD20-PEG 6-Rha的轻链分子量为23777Da，均与理论相符。
实施例3：美罗华抗体缀合物的亲和水平和抗体募集能力表征
流式细胞实验的实施方案为：
1)取生长状况良好的Raji细胞(CD20阳性)或K562细胞(CD20阴性)，重悬至4×10 5个/mL，移取100μL细胞悬液至预先装有100μL含50nmol/L抗体样品的无菌EP管，冰浴30min；
2)用200μL含10μg/mL的FITC耦合山羊抗人IgG抗体处理细胞(评估特异性亲和水平)；或先后用1％抗Rha兔血清和FITC耦合山羊抗兔IgG抗体处理细胞(评估抗Rha抗体募集能力)；
3)流式细胞仪Accuri C6进行检测。
特异性亲和水平结果如图2A所示，相对于空白对照，经美罗华抗体或抗体缀合物处理后的Raji细胞荧光明显增加，且两者增加程度相差无几。此外，CD20阴性的K562细胞则无明显变化，这说明该策略下Rha的修饰几乎不影响抗体对细胞表面CD20的特异性结合。
抗Rha抗体募集能力结果如图2B所示，相对于空白对照，仅经抗体缀合物处理后的Raji细胞有明显的荧光增长，表明美罗华抗体在被Rha修饰后，成功具备了募集抗Rha抗体至CD20阳性肿瘤细胞表面的能力。且图2B还表明抗体缀合物αCD20-PEG 3-Rha具备最高水平的抗Rha抗体募集能力。
实施例4：美罗华抗体缀合物的ADCC和CDC水平表征
细胞毒性试验的实施方案如下所示，对抗Rha抗体存在和不存在两种情况下的ADCC和CDC活性均进行评估。
ADCC实验：1)取生长状况良好的Raji细胞，重悬至4×10 5个/mL，移取50μL细胞悬液至96孔培养板中；2)立即加入50μL含不同浓度美罗华或美罗华抗体缀合物的PBS溶液，50μL 4％抗Rha兔血清(或相同体积的PBS)和50μL新鲜分离的PBMC，37℃处理4h；3)LDH试剂盒检测细胞毒性。
ADCC的结果如图3所示。在抗Rha抗体不存在的情况下(图3A)，美罗华和其缀合物的ADCC水平相差无几，在处理浓度为2.5nM时，均在20％左右；而在抗Rha抗体的存在下(图3B)，三种抗体缀合物的ADCC杀伤水平显著增强，最高值可达30-42％。表明本发明所提供的策略，可有效提升美罗华的ADCC活性。其中，缀合物αCD20-PEG 3-Rha的ADCC水平最高，在2.5nM的处理浓度下，可达41.3％。
CDC实验：1)取生长状况良好的Raji细胞，重悬至4×10 5个/mL，移取50μL细胞悬液至96孔培养板中；2)立即加入50μL含不同浓度美罗华或其缀合物的PBS溶液，50μL 4％抗Rha兔血清(或相同体积的PBS)和50μL 8％兔补体血清，37℃处理4h；3)LDH试剂盒检测细胞毒性。
CDC的结果如图4所示。在抗Rha抗体不存在的情况下(图4A)，美罗华和其缀合物的CDC水平相差无几，当处理浓度为2.5nM时，均在50％左右；而在抗Rha抗体的存在下(图4B)，三种抗体缀合物的ADCC杀伤水平显著增强，当处理浓度为2.5nM时，可达85-100％左右。表明本发明所提供的策略，可有效提升美罗华的CDC活性。其中，缀合物αCD20-PEG 3-Rha的CDC水平最高，在0.1nM的处理浓度下，即可达到69.3％，已经显著高于2.5nM原始抗体处理后的CDC水平(53.2％)。该结果表明在抗Rha抗体的存在下，若想达到相同的杀伤效率，αCD20-PEG 3-Rha的使用量仅需原始抗体的1/25甚至更少。
由以上实施例的结果可以看出，αCD20-PEG 3-Rha的ADCC、CDC水平最高，即ADCC、CDC杀伤水平得到显著增强。相对短链的αCD20-PEG 1-Rha和相对长链的αCD20-PEG 6-Rha的ADCC、CDC水平则相应较低，一方面，可能因为空间位阻原因，短链的αCD20-PEG 1-Rha与抗Rha抗体的募集水平受限，从而导致其ADCC、CDC杀伤水平无法得到提升；另一方面，可能因为亲和性原因，长链的αCD20-PEG 6-Rha与抗Rha抗体的亲和水平减弱，从而导致其ADCC、CDC杀伤水平反而受到抑制，并未实现如现有理论预期的正相关提成杀伤水平的效果。
以上所述仅是本发明的优选实施方式，应当指出：对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。

Claims (10)

  1. 一种抗体缀合物，其特征在于，由抗体分子经半抗原衍生物分子修饰形成，所述半抗原衍生物分子由半抗原、连接臂和耦合域组成。
  2. 据权利要求1抗体缀合物，其特征在于，所述半抗原为可募集相应特异性天然抗体的小分子，包括但不限于鼠李糖、αGal和2,4-二硝基苯。
  3. 根据权利要求1抗体缀合物，其特征在于，所述连接臂包括但不限于聚乙二醇链、碳链和肽链。
  4. 根据权利要求3所述的抗体缀合物，其特征在于，所述的连接臂为低聚乙二醇链PEG 3。
  5. 根据权利要求1抗体缀合物，其特征在于，所述耦合域为与抗体上巯基发生thio-ene或thio-yne反应的基团，包括但不限于SMCC及其他含马来酰亚胺的分子，还包括含乙烯基砜的分子、含丙烯酸脂/丙烯酸胺的分子、含3,4-二溴丁二酰亚胺的分子和含甲基丙烯酸酯的分子；耦合位置为抗体上二硫键还原后所形成的巯基。
  6. 根据权利要求1所述的抗体缀合物，其特征在于，所述抗体分子为单克隆抗体分子，包括但不限于抗CD20抗体、抗CD19抗体、抗CD30抗体、抗EGFR抗体、抗EGFRvIII抗体、抗HER2抗体、抗HER3抗体、抗PSMA抗体、抗VEGFR抗体、抗PD-L1抗体、抗cMET抗体、抗TGF-β抗体、抗MUC1抗体和抗Trop-2抗体。
  7. 根据权利要求1所述的抗体缀合物，其特征在于，所述半抗原衍生物分子包括：
    Figure PCTCN2021137352-appb-100001
  8. 根据权利要求7所述的抗体缀合物，其特征在于，所述半抗原衍生物的合成路径为：
    Figure PCTCN2021137352-appb-100002
    其中，n为正整数。
  9. 一种增强抗体分子免疫效应功能的方法，其特征在于，将半抗原衍生物分子修饰到抗体分子上，所述半抗原衍生物分子和抗体分子如权利要求1-8任一所述。
  10. 根据权利要求9所述的一种增强抗体分子免疫效应功能的方法，其特征在于，所述将半抗原衍生物分子修饰到抗体分子上制备抗体缀合物的方法包括以下步骤：
    1)将抗体脱盐置换到硼酸钠反应中；
    2)加入硫醇类还原剂TCEP避光震荡反应；
    3)反应完成后加入10倍当量的半抗原衍生物分子，反应后经半胱氨酸淬灭反应；
    4)超滤除去多余的小分子，得到相应的抗体缀合物。
PCT/CN2021/137352 2020-12-21 2021-12-13 一种抗体缀合物、增强抗体分子免疫效应功能的方法 WO2022135200A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP21909197.2A EP4265273A1 (en) 2020-12-21 2021-12-13 Antibody conjugate and method for enhancing immune effect function of antibody molecule
US18/337,631 US20230364257A1 (en) 2020-12-21 2023-06-20 Antibody conjugate and method for enhancing immune effect function of antibody molecule

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011516850.9 2020-12-21
CN202011516850.9A CN112618726B (zh) 2020-12-21 2020-12-21 一种抗体缀合物、增强抗体分子免疫效应功能的方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/337,631 Continuation US20230364257A1 (en) 2020-12-21 2023-06-20 Antibody conjugate and method for enhancing immune effect function of antibody molecule

Publications (1)

Publication Number Publication Date
WO2022135200A1 true WO2022135200A1 (zh) 2022-06-30

Family

ID=75320200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/137352 WO2022135200A1 (zh) 2020-12-21 2021-12-13 一种抗体缀合物、增强抗体分子免疫效应功能的方法

Country Status (4)

Country Link
US (1) US20230364257A1 (zh)
EP (1) EP4265273A1 (zh)
CN (1) CN112618726B (zh)
WO (1) WO2022135200A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041187A1 (en) * 1995-06-07 1996-12-19 Abbott Laboratories Improved hapten-peptide conjugates to detect anti-hiv-1 or anti-hiv-2 antibodies
US20140086949A1 (en) * 2011-02-09 2014-03-27 Kim D. Janda Ghrelin Mimetic Polypeptide Hapten Immunoconjugates Having Improved Solubility and Immunogenicity and Methods of Use Thereof
CN110420334A (zh) * 2019-08-19 2019-11-08 江南大学 一种药物缀合物和提高药物分子半衰期的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120096466A (ko) * 2009-10-05 2012-08-30 옵소닉 테라퓨틱스 인코포레이티드 항체 특이성을 재지시하기 위한 고 친화성 어댑터 분자
SG10201811124YA (en) * 2014-06-20 2019-01-30 Abgenomics Int Inc Her2 antibody-drug conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041187A1 (en) * 1995-06-07 1996-12-19 Abbott Laboratories Improved hapten-peptide conjugates to detect anti-hiv-1 or anti-hiv-2 antibodies
US20140086949A1 (en) * 2011-02-09 2014-03-27 Kim D. Janda Ghrelin Mimetic Polypeptide Hapten Immunoconjugates Having Improved Solubility and Immunogenicity and Methods of Use Thereof
CN110420334A (zh) * 2019-08-19 2019-11-08 江南大学 一种药物缀合物和提高药物分子半衰期的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LI CHEN, DAI SHIJIE, CAO AIJIE, ZHOU ZHIFANG, WU ZHIMENG: "Design and synthesis of rhamnose-modified exenatide conjugate by sortase A-mediated ligation", JOURNAL OF CARBOHYDRATE CHEMISTRY, vol. 38, no. 3, 19 May 2019 (2019-05-19), UK , pages 167 - 178, XP009537687, ISSN: 0732-8303, DOI: 10.1080/07328303.2019.1609021 *
SHERIDAN RACHAEL T. C., HUDON JONATHAN, HANK JACQUELYN A., SONDEL PAUL M., KIESSLING LAURA L.: "Rhamnose Glycoconjugates for the Recruitment of Endogenous Anti-Carbohydrate Antibodies to Tumor Cells", CHEMBIOCHEM, vol. 15, no. 10, 7 July 2014 (2014-07-07), pages 1393 - 1398, XP055899988, ISSN: 1439-4227, DOI: 10.1002/cbic.201402019 *
ZHOU KUN, HONG HAOFEI, LIN HAN, GONG LIANG, LI DAN, SHI JIE, ZHOU ZHIFANG, XU FEI, WU ZHIMENG: "Chemical Synthesis of Antibody–Hapten Conjugates Capable of Recruiting the Endogenous Antibody to Magnify the Fc Effector Immunity of Antibody for Cancer Immunotherapy", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 65, no. 1, 13 January 2022 (2022-01-13), US , pages 323 - 332, XP055944672, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.1c01480 *

Also Published As

Publication number Publication date
CN112618726A (zh) 2021-04-09
EP4265273A9 (en) 2024-03-06
EP4265273A1 (en) 2023-10-25
US20230364257A1 (en) 2023-11-16
CN112618726B (zh) 2022-11-11

Similar Documents

Publication Publication Date Title
JP7055742B6 (ja) フタロシアニン色素コンジュゲートおよびその保存法
JP3583420B2 (ja) 二特異的試薬を用いた標的免疫化
JP7073487B2 (ja) 操作された抗体化合物およびこれらの抱合体
JP2019536740A5 (zh)
JP2019532056A5 (zh)
JPS61227532A (ja) 抗体ハイブリツド分子およびその製造方法
EP3487883A1 (en) Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
JPS61500789A (ja) モノクロ−ナル抗−ヒト乳癌抗体
HUT53153A (en) Process for producing bispecific monoclonal antibody
JPS58208238A (ja) 共有結合によつて酵素と抗体を結合させる新しい共役物とこの共役物を用いた医薬会合
EP3166638A1 (en) Payload-polymer-protein conjugates
US20220380721A1 (en) Method for coupling antibody to surface of cell and method for applying cell coupled with the antibody
TWI726217B (zh) 含有抗globo h抗體之抗體－藥物共軛物及其用途
TW201718021A (zh) 包含金屬奈米粒子、連接物及抗體之複合物
WO2022135200A1 (zh) 一种抗体缀合物、增强抗体分子免疫效应功能的方法
US4806494A (en) Monoclonal antibody against ovarian cancer cells (OVB-3)
CN110759940A (zh) 连接子、含连接子的抗体偶联药物及连接子的用途
JPWO2019212965A5 (zh)
JP2016524459A (ja) 診断および治療目的のための抗体−ウレアーゼコンジュゲートの使用
JP2022529956A (ja) 活性化ｃａｒ－ｔ細胞に由来する細胞外小胞
Koumarianou et al. Development of a novel bi-specific monoclonal antibody approach for tumour targeting
CN114409766B (zh) 一种eb病毒的中和性抗体及其应用
Li et al. Chemical conjugation of a novel antibody-interleukin 2 immunoconjugate against c-erbB-2 product
WO2021258140A1 (en) Cd83 binding protein conjugates for treating lymphoma
JPH0193538A (ja) 抗腫瘍剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21909197

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021909197

Country of ref document: EP

Effective date: 20230721